Immunotherapy for Melanoma: Systemic and Locoregional Approaches, Mechanisms, and Future Directions
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Dermato-Oncology".
Deadline for manuscript submissions: 30 November 2026 | Viewed by 117
Special Issue Editors
Interests: soft tissue sarcoma; immuno-oncology; skin malignancies; the effect of obesity on treatment response
Special Issues, Collections and Topics in MDPI journals
Interests: skin and soft tissue malignancies; melanoma; nonmelanoma skin cancers; retroperitoneal and extremity sarcoma; neuroendocrine tumors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immune checkpoint blockade has transformed the treatment landscape for advanced melanoma, enabling durable responses and long-term survival in a subset of patients. However, many patients exhibit primary resistance or ultimately develop disease progression. These challenges are driven by complex interactions between tumor-intrinsic pathways, the tumor microenvironment, host immunity, and systemic factors such as metabolism and the microbiome. A deeper understanding of these mechanisms is essential to improve therapeutic durability and expand the population of patients who benefit from immunotherapy.
Recent advances include adoptive cell therapies, bispecific antibodies, intratumoral and intralesional approaches, cancer vaccines, and rational combination strategies that integrate targeted therapy, radiation, and metabolic modulation. In parallel, developments in biomarker discovery, including genomic profiling as well as single-cell and spatial analyses, offer new opportunities to refine patient selection and guide treatment decisions.
This Special Issue aims to highlight recent advances in melanoma immunotherapy, focusing on mechanisms of response and resistance, biomarker development, and emerging therapeutic strategies. We welcome original and translational studies that advance understanding of tumor–immune interactions and inform clinically relevant approaches to improve outcomes.
Topics include the following: resistance mechanisms; tumor microenvironment; metabolism; biomarkers; adoptive cell therapy; intratumoral and intralesional immunotherapy; cancer vaccines; combination strategies; microbiome; immune-related toxicity; and neoadjuvant and adjuvant immunotherapy.
We look forward to hearing from you.
Dr. Russell G. Witt
Dr. Sarah Bateni
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- melanoma
- immunotherapy
- checkpoint blockade
- tumor microenvironment
- resistance
- biomarkers
- intratumoral therapy
- adoptive cell therapy
- cancer vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
